<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11506488</article-id><article-id pub-id-type="pmc">2364084</article-id><article-id pub-id-type="pii">6691953</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.1953</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) &#x000b1; folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bensma&#x000ef;ne</surname><given-names>M A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Marty</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gramont</surname><given-names>A de</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Brienza</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>L&#x000e9;vi</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ducreux</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Fran&#x000e7;ois</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Gamelin</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Bleiberg</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Cvitkovic</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Cvitkovic et Associ&#x000e9;s Consultants, 18&#x02013;20 rue Pasteur, Kremlin-Bic&#x000ea;tre, 94278</aff><aff id="aff2"><label>2</label>H&#x000f4;pital Saint-Louis, 1 avenue Claude Vellefaux, Paris, 75010</aff><aff id="aff3"><label>3</label>H&#x000f4;pital Saint-Antoine, 184 rue du Fg St Antoine, Paris, 75012</aff><aff id="aff4"><label>4</label>Debioclinic, 2 rue du Nouveau Bercy, 94220 Charenton le Pont</aff><aff id="aff5"><label>5</label>H&#x000f4;pital Paul Brousse, 14 avenue Paul Vaillant Couturier, Villejuif Cedex, 94805</aff><aff id="aff6"><label>6</label>Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif Cedex, 94805</aff><aff id="aff7"><label>7</label>Centre Lacassagne, 33 avenue de Valombrose, Nice Cedex 01, 06050</aff><aff id="aff8"><label>8</label>Centre Paul Papin, 2 rue du Moll, Angers Cedex 01, 49033, France and</aff><aff id="aff9"><label>9</label>Institut Jules Bordet, 1 rue H&#x000e9;ger-Bordet, Brussels, 1000, Belgium</aff><pub-date pub-type="ppub"><month>08</month><year>2001</year></pub-date><volume>85</volume><issue>4</issue><fpage>509</fpage><lpage>517</lpage><history><date date-type="received"><day>08</day><month>12</month><year>2000</year></date><date date-type="rev-recd"><day>17</day><month>05</month><year>2001</year></date><date date-type="accepted"><day>01</day><month>06</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>A statistical analysis was performed on the patient data collected from two compassionate-use programmes using oxaliplatin (Eloxatin&#x000ae;) + 5-fluorouracil (5-FU) &#x000b1; folinic acid (FA), to identify predictive factors for oxaliplatin-based salvage treatment in patients with 5-FU-resistant advanced colorectal cancer (ACRC). 481 5-FU-resistant ACRC patients, most with performance status &#x02264; 2, &#x02265; 3 involved sites, and &#x02265; 2 prior lines of chemotherapy, received oxaliplatin + 5-FU &#x000b1; FA. Prognostic factors associated with overall response rate (ORR), time to progression (TTP) and overall survival (OS) were identified using univariate and multivariate logistic and/or Cox proportional hazards analyses. The ORR was 16&#x00025; (95&#x00025; CI: 13&#x02013;20), the median TTP was 4.2 months (95&#x00025; CI: 3.4&#x02013;4.6), and the median OS was 9.6 months (95&#x00025; CI: 8.6&#x02013;10.6). The multivariate analysis indicated poor (&#x02265; 2 WHO) performance status (PS), a large number of prior chemotherapy regimens (&#x02265; 3), a low baseline haemoglobin level (&#x0003c; 10&#x02008;g/dl), and a triweekly (vs biweekly) treatment administration schedule as significantly associated (<italic>P</italic>&#x0003c; 0.05) with a lower ORR. Sex (male), number of organs involved (&#x02265;3) and alkaline phosphatase (AP) level (&#x02265; 2 &#x000d7; the upper limit of normal) were associated (<italic>P</italic>&#x0003c; 0.05) with shorter TTP. Poor PS, a large number of organs involved, and elevated AP were independently and significantly correlated with shorter OS. Our analysis identified a relationship between efficacy results of oxaliplatin + 5-FU &#x000b1; FA treatment in 5-FU-resistant ACRC patients and baseline prognostic factors related to PS, extent of disease and number of prior regimens. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>clinical resistance</kwd><kwd>multivariate analysis</kwd><kwd>salvage chemotherapy</kwd></kwd-group></article-meta></front></article>


